Jung Ki Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jung Ki Kim has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Eileen M. Crimmins
University of Southern California
17 shared publications Eileen M. Crimmins
Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA
6 shared publications- Bharat Thyagarajan
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis
5 shared publications - Jessica D. Faul
Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA.
5 shared publications Eileen Crimmins
Leonard Davis School of Gerontology University of Southern California Los Angeles California USA
3 shared publications- Eric T. Klopack
Indiana University
3 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (7) , 100595
Epigenetic aging and blood based neurodegeneration markers in LASI-DAD
- 14 May 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (7) , 100595
Open AccessEpigenetic aging and blood based neurodegeneration markers in LASI-DAD
- Open Access
- 20 January 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (3)
Association between shingles vaccination and slower biological aging: evidence from a US population-based cohort study
There is growing interest in whether adult vaccines such as shingles vaccine may slow biological aging beyond preventing acute infections. Using data from the nationally representative US Health and Retirement Study, we examined whether shingles vaccination is associated with more favorable profiles across 7 biological aging domains: inflammation, innate and adaptive immunity, cardiovascular hemodynamics, neurodegeneration, and epigenetic and transcriptomic aging, as well as a composite biological aging score. Analyses included adults aged ≥ 70 in 2016 (n = 3884), with biological measures drawn from venous blood, flow cytometry, and physical assessments. Weighted linear regressions adjusted for sociodemographic and health covariates. Shingles vaccination was significantly associated with lower inflammation scores (b = −0.14, p = .0027), slower epigenetic (b = −0.17, p = .0001) and transcriptomic aging (b = −0.19, p < .0001), and a lower composite biological aging score (b = −0.18, p = .0002), suggesting potential benefits for systemic inflammation, molecular and overall biological aging. In contrast, vaccination was linked to higher adaptive immunity scores (b = 0.09, p = .0133), an unexpected finding warranting further investigation. Timing analyses indicated that epigenetic, transcriptomic and overall composite biological aging improvements were most pronounced within 3 years postvaccination, with slower aging persisting beyond this window. The results support the hypothesis that shingles vaccination may influence key biological systems relevant to aging, though effects appear domain-specific and vary over time. Longitudinal studies are needed to confirm these patterns and explore implications for long-term health. This study adds to emerging evidence that vaccines could play a role in strategies to promote healthy aging by modulating biological systems beyond infection prevention.
- 20 January 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (3)
Open AccessAssociation between shingles vaccination and slower biological aging: evidence from a US population-based cohort study
There is growing interest in whether adult vaccines such as shingles vaccine may slow biological aging beyond preventing acute infections. Using data from the nationally representative US Health and Retirement Study, we examined whether shingles vaccination is associated with more favorable profiles across 7 biological aging domains: inflammation, innate and adaptive immunity, cardiovascular hemodynamics, neurodegeneration, and epigenetic and transcriptomic aging, as well as a composite biological aging score. Analyses included adults aged ≥ 70 in 2016 (n = 3884), with biological measures drawn from venous blood, flow cytometry, and physical assessments. Weighted linear regressions adjusted for sociodemographic and health covariates. Shingles vaccination was significantly associated with lower inflammation scores (b = −0.14, p = .0027), slower epigenetic (b = −0.17, p = .0001) and transcriptomic aging (b = −0.19, p < .0001), and a lower composite biological aging score (b = −0.18, p = .0002), suggesting potential benefits for systemic inflammation, molecular and overall biological aging. In contrast, vaccination was linked to higher adaptive immunity scores (b = 0.09, p = .0133), an unexpected finding warranting further investigation. Timing analyses indicated that epigenetic, transcriptomic and overall composite biological aging improvements were most pronounced within 3 years postvaccination, with slower aging persisting beyond this window. The results support the hypothesis that shingles vaccination may influence key biological systems relevant to aging, though effects appear domain-specific and vary over time. Longitudinal studies are needed to confirm these patterns and explore implications for long-term health. This study adds to emerging evidence that vaccines could play a role in strategies to promote healthy aging by modulating biological systems beyond infection prevention.
- Open Access
The association of blood-based biomarkers of neuropathology with cognitive performance and incident dementia in a diverse, nationally-representative sample of US adults
INTRODUCTION: The association of blood-based biomarkers of neuropathology with cognition, dementia, and mortality and how these association potentially differ by race/ethnicity, has not been examined in large, diverse, nationally-representative samples of adults. METHODS: The sample included Health and Retirement Study (HRS) respondents over age 50 with blood-based neuropathology biomarker, demographic, and cognitive data (n=4,214). A β -40, A β -42, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were measured in plasma (Quanterix Neurology 4-Plex E kit), and phosphorylated tau (pTau-181) was measured in serum (Quanterix Advantage V2.0 kit). Cognitive tests included immediate and delayed word recall, serial 7s, and backward counting (total score 0-27). Dementia classification relied on a diagnostic algorithm previously validated in the HRS. RESULTS: When each biomarker was analyzed individually, higher A β -42/A β -40 ratio was associated with better cognitive function among non-Hispanic (NH) whites. Higher NfL was associated with worse cognitive function in the total sample and in each race/ethnic group (NH white, NH black, and Hispanic). Higher pTau-181 was associated with worse cognitive function in the total and NH white sample. Higher GFAP was related to worse cognitive function in the total sample only. In a model that included all four biomarkers, NfL remained significantly related to cognitive performance in the total sample and in each race/ethnic group, and irrespective of APOE status. NfL was predictive of 6-year incident dementia in our sample (OR=1.33). All four markers significantly predicted 6-year mortality. DISCUSSION: In a large nationally-representative sample of US adults, we found that NfL was the most consistent predictor of cross-sectional and incident dementia 6 years post blood collection. NfL was also the most consistent predictor across race/ethnic groups examined in our study. Highlights: There are currently limited data on blood-based biomarkers of neuropathology as predictors of cognitive performance and incident dementia in diverse, population-based cohort studies. We used data from the Health and Retirement Study (n-=4,214) to examine the association between blood-based biomarkers of neuropathology and cognitive function, as well as their association with incident dementia and mortality 4 years after measurement. Mean levels of A β -42/A β -40 were similar across race/ethnic groups and age groups in this US population-representative sample where selection effects have been minimized. Average NfL was higher among non-Hispanic blacks and Hispanics; GFAP was higher among non-Hispanic blacks as compared to non-Hispanic whites. In a model that included all four biomarkers, NfL remained significantly related to cognitive performance in the total sample and in each race/ethnic group. NfL was associated with incident dementia 6 years after measurement in the total sample. A β -42/A β -40 ratio was predictive of 6-year incident dementia among those with at least one APOE e4 allele.
Open AccessThe association of blood-based biomarkers of neuropathology with cognitive performance and incident dementia in a diverse, nationally-representative sample of US adults
INTRODUCTION: The association of blood-based biomarkers of neuropathology with cognition, dementia, and mortality and how these association potentially differ by race/ethnicity, has not been examined in large, diverse, nationally-representative samples of adults. METHODS: The sample included Health and Retirement Study (HRS) respondents over age 50 with blood-based neuropathology biomarker, demographic, and cognitive data (n=4,214). A β -40, A β -42, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were measured in plasma (Quanterix Neurology 4-Plex E kit), and phosphorylated tau (pTau-181) was measured in serum (Quanterix Advantage V2.0 kit). Cognitive tests included immediate and delayed word recall, serial 7s, and backward counting (total score 0-27). Dementia classification relied on a diagnostic algorithm previously validated in the HRS. RESULTS: When each biomarker was analyzed individually, higher A β -42/A β -40 ratio was associated with better cognitive function among non-Hispanic (NH) whites. Higher NfL was associated with worse cognitive function in the total sample and in each race/ethnic group (NH white, NH black, and Hispanic). Higher pTau-181 was associated with worse cognitive function in the total and NH white sample. Higher GFAP was related to worse cognitive function in the total sample only. In a model that included all four biomarkers, NfL remained significantly related to cognitive performance in the total sample and in each race/ethnic group, and irrespective of APOE status. NfL was predictive of 6-year incident dementia in our sample (OR=1.33). All four markers significantly predicted 6-year mortality. DISCUSSION: In a large nationally-representative sample of US adults, we found that NfL was the most consistent predictor of cross-sectional and incident dementia 6 years post blood collection. NfL was also the most consistent predictor across race/ethnic groups examined in our study. Highlights: There are currently limited data on blood-based biomarkers of neuropathology as predictors of cognitive performance and incident dementia in diverse, population-based cohort studies. We used data from the Health and Retirement Study (n-=4,214) to examine the association between blood-based biomarkers of neuropathology and cognitive function, as well as their association with incident dementia and mortality 4 years after measurement. Mean levels of A β -42/A β -40 were similar across race/ethnic groups and age groups in this US population-representative sample where selection effects have been minimized. Average NfL was higher among non-Hispanic blacks and Hispanics; GFAP was higher among non-Hispanic blacks as compared to non-Hispanic whites. In a model that included all four biomarkers, NfL remained significantly related to cognitive performance in the total sample and in each race/ethnic group. NfL was associated with incident dementia 6 years after measurement in the total sample. A β -42/A β -40 ratio was predictive of 6-year incident dementia among those with at least one APOE e4 allele.
- Open Access
- 30 December 2025
- Published by Springer Nature in Research Square
Impaired lung function is associated with elevated blood biomarkers of AD/ADRD: Unraveling the interplay with risk of dementia
Background and Objectives: Impaired lung function (ILF) has been associated with cognitive decline and dementia risk in multiple cohorts, yet the role of circulating Alzheimer disease (AD) biomarkers in this relationship is not well understood. We aim to assess the associations between ILF and AD biomarkers and to determine whether these biomarkers mediate the relationship between ILF and incident dementia. Methods: Serum p-Tau181 and plasma Aβ42/40, NfL, and GFAP were measured in 4,072 participants (mean age 66 ± 10; 59% women) in the 2016 Health and Retirement Study. Peak Expiratory Flow (PEF) was assessed in 2012/2014, and cognitive function was measured at four time points between 2014 and 2020 (every two years) to determine dementia status. Impaired lung function (ILF) was defined as predicted PEF <80%. Multivariable regression examined associations between lung function and AD biomarkers; causal mediation analysis evaluated their role in linking lung function to incident dementia. Results: In total, 881 (21.6%) participants had ILF and 272 (6.8%) participants developed dementia. After adjusting for demographics, education, BMI, smoking, comorbidities, inflammation, eGFR and APOE e4 , ILF was associated with a higher risk of dementia (HR=1.74; 95% CI (1.34, 225)). Individuals with ILF had 0.10 SD higher NfL (SE= 0.03; p= 0.004) and 0.09 SD higher p-Tau 181 (SE= 0.03; p= 0.002) compared to those without ILF. NfL mediated 7.3% (p=0.01) of the total effect of ILF on dementia, while p-Tau 181 mediated 5% (p=0.05) of this association. Discussion: ILF was associated with elevated levels of neurodegeneration markers NfL and p-Tau 181, which partially mediated its relationship with dementia risk. These findings highlight the importance of monitoring blood protein biomarkers in individuals with impaired lung health to facilitate early interventions.
- 30 December 2025
- Published by Springer Nature in Research Square
Open AccessImpaired lung function is associated with elevated blood biomarkers of AD/ADRD: Unraveling the interplay with risk of dementia
Background and Objectives: Impaired lung function (ILF) has been associated with cognitive decline and dementia risk in multiple cohorts, yet the role of circulating Alzheimer disease (AD) biomarkers in this relationship is not well understood. We aim to assess the associations between ILF and AD biomarkers and to determine whether these biomarkers mediate the relationship between ILF and incident dementia. Methods: Serum p-Tau181 and plasma Aβ42/40, NfL, and GFAP were measured in 4,072 participants (mean age 66 ± 10; 59% women) in the 2016 Health and Retirement Study. Peak Expiratory Flow (PEF) was assessed in 2012/2014, and cognitive function was measured at four time points between 2014 and 2020 (every two years) to determine dementia status. Impaired lung function (ILF) was defined as predicted PEF <80%. Multivariable regression examined associations between lung function and AD biomarkers; causal mediation analysis evaluated their role in linking lung function to incident dementia. Results: In total, 881 (21.6%) participants had ILF and 272 (6.8%) participants developed dementia. After adjusting for demographics, education, BMI, smoking, comorbidities, inflammation, eGFR and APOE e4 , ILF was associated with a higher risk of dementia (HR=1.74; 95% CI (1.34, 225)). Individuals with ILF had 0.10 SD higher NfL (SE= 0.03; p= 0.004) and 0.09 SD higher p-Tau 181 (SE= 0.03; p= 0.002) compared to those without ILF. NfL mediated 7.3% (p=0.01) of the total effect of ILF on dementia, while p-Tau 181 mediated 5% (p=0.05) of this association. Discussion: ILF was associated with elevated levels of neurodegeneration markers NfL and p-Tau 181, which partially mediated its relationship with dementia risk. These findings highlight the importance of monitoring blood protein biomarkers in individuals with impaired lung health to facilitate early interventions.
- Open Access
- 15 December 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (3) , 800-806
Cardiometabolic‐Inflammatory Risk Factors and Cognitive Decline Among Older Indians—Report From a Nationally Representative, Longitudinal Study
Background: Rapid increase in cardiometabolic diseases in India may contribute to increased incidence of late‐life cognitive impairment. This study focuses on associations between baseline cardiometabolic risk factors and subsequent decline in cognitive function among older adults in India, leveraging data from two waves (Wave 1: 2017–2020, Wave 2: 2022–2024) of the Longitudinal Aging Study in India–Diagnostic Assessment of Dementia (LASI‐DAD). Methods: Analysis included longitudinal data of 1554 study participants. A summary measure of different cognitive functional domains was used. Cognitive decline was defined as annual decline in cognitive score ≥ 0.05 times the standard deviation of the summary score. Cardiometabolic risk was characterized using cardiovascular, metabolic, and inflammatory biomarkers. Multivariate, multinomial logistic regression analysis was used to examine the associations between cardiometabolic risk and cognitive decline. Results: At baseline, 71.7% of the sample had elevated homocysteine levels, 44.4% had elevated blood pressure, 23% had elevated glycosylated hemoglobin (HbA1c), and 6.7% had elevated uric acid levels. Between the two waves, 34.8% experienced significant cognitive decline, while 35.6% died. Multivariate multinomial logistic regression showed significant cognitive decline was associated with elevated blood pressure [odds ratio (OR): 1.7, 95% confidence interval (CI) 1.3–2.2], elevated HbA1c (OR: 1.1, 95% CI: 1.0–1.2), being overweight (OR: 1.4, 95% CI: 1.0–2.0), and elevated uric acid level (OR: 1.2, 95% CI: 1.0–1.3). Those with hypertension had 1.5 times higher odds of mortality (95% confidence interval: 1.2–2.0), while those with diabetes mellitus or elevated pro‐brain natriuretic peptide had 1.2 times (95% CI: 1.1–1.4), and 1.8 times (95% CI: 1.1–1.4) higher odds of mortality. Conclusion: Cardiometabolic risk factors play a significant role in late‐life cognitive decline and death among older Indians. These longitudinal relationships from LASI‐DAD highlight potentially modifiable risk factors and inform potential prevention policies.
- 15 December 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (3) , 800-806
Open AccessCardiometabolic‐Inflammatory Risk Factors and Cognitive Decline Among Older Indians—Report From a Nationally Representative, Longitudinal Study
Background: Rapid increase in cardiometabolic diseases in India may contribute to increased incidence of late‐life cognitive impairment. This study focuses on associations between baseline cardiometabolic risk factors and subsequent decline in cognitive function among older adults in India, leveraging data from two waves (Wave 1: 2017–2020, Wave 2: 2022–2024) of the Longitudinal Aging Study in India–Diagnostic Assessment of Dementia (LASI‐DAD). Methods: Analysis included longitudinal data of 1554 study participants. A summary measure of different cognitive functional domains was used. Cognitive decline was defined as annual decline in cognitive score ≥ 0.05 times the standard deviation of the summary score. Cardiometabolic risk was characterized using cardiovascular, metabolic, and inflammatory biomarkers. Multivariate, multinomial logistic regression analysis was used to examine the associations between cardiometabolic risk and cognitive decline. Results: At baseline, 71.7% of the sample had elevated homocysteine levels, 44.4% had elevated blood pressure, 23% had elevated glycosylated hemoglobin (HbA1c), and 6.7% had elevated uric acid levels. Between the two waves, 34.8% experienced significant cognitive decline, while 35.6% died. Multivariate multinomial logistic regression showed significant cognitive decline was associated with elevated blood pressure [odds ratio (OR): 1.7, 95% confidence interval (CI) 1.3–2.2], elevated HbA1c (OR: 1.1, 95% CI: 1.0–1.2), being overweight (OR: 1.4, 95% CI: 1.0–2.0), and elevated uric acid level (OR: 1.2, 95% CI: 1.0–1.3). Those with hypertension had 1.5 times higher odds of mortality (95% confidence interval: 1.2–2.0), while those with diabetes mellitus or elevated pro‐brain natriuretic peptide had 1.2 times (95% CI: 1.1–1.4), and 1.8 times (95% CI: 1.1–1.4) higher odds of mortality. Conclusion: Cardiometabolic risk factors play a significant role in late‐life cognitive decline and death among older Indians. These longitudinal relationships from LASI‐DAD highlight potentially modifiable risk factors and inform potential prevention policies.
- 20 November 2025
- Published by SAGE Publications in Journal of Applied Gerontology
- Vol. 45 (11) , 2210-2220
Cognitive Decline and Dementia Trajectories by Dizziness Status in Older Adults
Dizziness is common in later life and may signal early cognitive vulnerability, but its long-term implications are not well-understood. Data from six waves of the Health and Retirement Study (2000–2020) were used to examine the association of persistent dizziness, defined as dizziness reported in ≥2 waves on cognitive outcomes including longitudinal cognitive score trajectories, dementia risk, and incidence, with age, sex, education, multimorbidity, and polypharmacy controlled. Individuals with persistent dizziness had lower baseline cognitive scores and significantly faster decline over time (β = −0.24, p < .001). Persistent dizziness was associated with a faster rise in dementia risk over time (OR = 1.23, p < .001) and a 36% higher hazard of incident dementia (HR = 1.36, p = 0.004). Persistent dizziness is linked to steeper cognitive decline and elevated dementia risk. These findings support dizziness as a potential early indicator of cognitive vulnerability and highlight its value for screening and preventive care in aging populations.
- 20 November 2025
- Published by SAGE Publications in Journal of Applied Gerontology
- Vol. 45 (11) , 2210-2220
Cognitive Decline and Dementia Trajectories by Dizziness Status in Older Adults
Dizziness is common in later life and may signal early cognitive vulnerability, but its long-term implications are not well-understood. Data from six waves of the Health and Retirement Study (2000–2020) were used to examine the association of persistent dizziness, defined as dizziness reported in ≥2 waves on cognitive outcomes including longitudinal cognitive score trajectories, dementia risk, and incidence, with age, sex, education, multimorbidity, and polypharmacy controlled. Individuals with persistent dizziness had lower baseline cognitive scores and significantly faster decline over time (β = −0.24, p < .001). Persistent dizziness was associated with a faster rise in dementia risk over time (OR = 1.23, p < .001) and a 36% higher hazard of incident dementia (HR = 1.36, p = 0.004). Persistent dizziness is linked to steeper cognitive decline and elevated dementia risk. These findings support dizziness as a potential early indicator of cognitive vulnerability and highlight its value for screening and preventive care in aging populations.
- Open Access
- 10 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Gene expression composite scores of cellular senescence predict aging health outcomes in the Health and Retirement Study
Cellular senescence, a hallmark of aging, can be quantified by the gene expression composite scores for the canonical senescence pathway (CSP), senescence initiating pathway (SIP), senescence response pathway (SRP), a summary of the three, and the SenMayo gene list; however, these have not been probed in representative populations. Using RNA sequencing data from the U.S. representative Health and Retirement Study (HRS) sample (N = 3580), we examine how these composite scores relate to sociobehavioral factors and aging-related outcomes. Senescence scores generally increase with age except for CSP. Higher scores are observed in women and individuals with class II obesity. All scores, except for CSP, are associated with accelerated epigenetic aging, physiological dysregulation, multimorbidity, cognitive decline, and 6-year mortality (all p < 0.05). These associations largely persist after adjustment for DunedinPACE. Our findings suggest that cellular senescence gene expression composite scores capture meaningful variation in aging-related health and complement existing epigenetic aging biomarkers.
- 10 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Open AccessGene expression composite scores of cellular senescence predict aging health outcomes in the Health and Retirement Study
Cellular senescence, a hallmark of aging, can be quantified by the gene expression composite scores for the canonical senescence pathway (CSP), senescence initiating pathway (SIP), senescence response pathway (SRP), a summary of the three, and the SenMayo gene list; however, these have not been probed in representative populations. Using RNA sequencing data from the U.S. representative Health and Retirement Study (HRS) sample (N = 3580), we examine how these composite scores relate to sociobehavioral factors and aging-related outcomes. Senescence scores generally increase with age except for CSP. Higher scores are observed in women and individuals with class II obesity. All scores, except for CSP, are associated with accelerated epigenetic aging, physiological dysregulation, multimorbidity, cognitive decline, and 6-year mortality (all p < 0.05). These associations largely persist after adjustment for DunedinPACE. Our findings suggest that cellular senescence gene expression composite scores capture meaningful variation in aging-related health and complement existing epigenetic aging biomarkers.
- Open Access
- 21 August 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (12) , 3705-3713
Association of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS)
This study examines associations between blood-based neurodegenerative biomarkers and cognitive functioning in nationally representative samples of older adults in India and the United States. Using data from the Longitudinal Aging Study in India-Diagnostic Assessment of Dementia (LASI-DAD) and the Health and Retirement Study (HRS), we analyzed 4 biomarkers—the ratio of Amyloid beta 42-40 (Aβ42/Aβ40), Glial Fibrillary Acidic Protein (GFAP), Neurofilament Light Chain (NfL), and Phosphorylated Tau at Threonine 181 (pTau181)—in relation to cognitive outcomes. Higher levels of GFAP and NfL were associated with worse cognitive function and a greater likelihood of dementia in both populations. GFAP and NfL were also associated with cognitive decline in the HRS, but not in LASI-DAD. Higher Aβ42/Aβ40 ratio was associated with worse cognitive functioning and more dementia in HRS; on the other hand, higher levels of the Aβ42/Aβ40 ratio were significantly linked with better cognitive functioning in LASI-DAD. pTau181 was generally not associated with cognitive functioning in either country. The associations of the whole set of markers with subsequent mortality suggest they may serve as markers for general aging. This article is part of a Special Collection on Cross-National Gerontology.
- 21 August 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (12) , 3705-3713
Open AccessAssociation of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS)
This study examines associations between blood-based neurodegenerative biomarkers and cognitive functioning in nationally representative samples of older adults in India and the United States. Using data from the Longitudinal Aging Study in India-Diagnostic Assessment of Dementia (LASI-DAD) and the Health and Retirement Study (HRS), we analyzed 4 biomarkers—the ratio of Amyloid beta 42-40 (Aβ42/Aβ40), Glial Fibrillary Acidic Protein (GFAP), Neurofilament Light Chain (NfL), and Phosphorylated Tau at Threonine 181 (pTau181)—in relation to cognitive outcomes. Higher levels of GFAP and NfL were associated with worse cognitive function and a greater likelihood of dementia in both populations. GFAP and NfL were also associated with cognitive decline in the HRS, but not in LASI-DAD. Higher Aβ42/Aβ40 ratio was associated with worse cognitive functioning and more dementia in HRS; on the other hand, higher levels of the Aβ42/Aβ40 ratio were significantly linked with better cognitive functioning in LASI-DAD. pTau181 was generally not associated with cognitive functioning in either country. The associations of the whole set of markers with subsequent mortality suggest they may serve as markers for general aging. This article is part of a Special Collection on Cross-National Gerontology.
- 1 August 2025
- Published by Duke University Press in Demography
- Vol. 62 (4) , 1367-1388
Increasing Educational Inequality in Biological Aging Among U.S. Adults Aged 50–79 From 1988–1994 to 2015–2018
Educational inequality in health has been increasing in the United States. The growth in health inequality has not been limited to specific conditions but has been observed across a wide range of outcomes, including disability, multimorbidity, self-rated health, and mortality. This study used data for adults aged 50–79 from the National Health and Nutrition Examination Survey to assess changes in biological aging across education groups over a 25-year period. We found that while biological aging slowed for each education group, educational inequality increased owing to greater improvements among those with the highest education levels. Specifically, biological age differences between adults with 0–11 years of schooling and adults with 16+ years of schooling grew from one year in 1988–1994 to almost two years in 2015–2018. Growing inequality in biological aging was not attenuated by changes in smoking, obesity, or medication use. Overall, these results point to an increasing difference in physiological dysregulation by education among U.S. older adults, which might remain a source of greater and growing inequality in morbidity, disability, and mortality in the near future.
- 1 August 2025
- Published by Duke University Press in Demography
- Vol. 62 (4) , 1367-1388
Increasing Educational Inequality in Biological Aging Among U.S. Adults Aged 50–79 From 1988–1994 to 2015–2018
Educational inequality in health has been increasing in the United States. The growth in health inequality has not been limited to specific conditions but has been observed across a wide range of outcomes, including disability, multimorbidity, self-rated health, and mortality. This study used data for adults aged 50–79 from the National Health and Nutrition Examination Survey to assess changes in biological aging across education groups over a 25-year period. We found that while biological aging slowed for each education group, educational inequality increased owing to greater improvements among those with the highest education levels. Specifically, biological age differences between adults with 0–11 years of schooling and adults with 16+ years of schooling grew from one year in 1988–1994 to almost two years in 2015–2018. Growing inequality in biological aging was not attenuated by changes in smoking, obesity, or medication use. Overall, these results point to an increasing difference in physiological dysregulation by education among U.S. older adults, which might remain a source of greater and growing inequality in morbidity, disability, and mortality in the near future.
- Open Access
- 3 June 2025
- Published by Wolters Kluwer Health in Menopause
- Vol. 32 (8) , 692-701
Early menopause, hysterectomy, and biological aging: Health and Retirement Study
Objective: This study examines the association between the timing of menopause and hysterectomy and biological aging, focusing on epigenetic and physiological aging markers. Methods: Data were analyzed from women aged 56 and over in the nationally representative Health and Retirement Study (HRS). Regressions of biological aging measured by accelerated epigenetic aging and biological age based on physiological dysregulation on menopause/hysterectomy history were conducted to examine associations of normal-aged and early menopause with and without hysterectomy with biological aging. Results: Hysterectomy, whether following normal-aged or early menopause, or in younger ages, was significantly associated with markers of accelerated biological aging. Women with early menopause or hysterectomy showed accelerated epigenetic aging. Early menopause was associated with accelerated physiological dysregulation only when combined with hysterectomy, suggesting that surgical menopause may be related to accelerated systemic aging processes. Epigenetic clocks were associated with early cellular and molecular aging changes linked to natural early menopause, while physiological dysregulation was associated with the cumulative systemic impacts related to hysterectomy. Conclusions: This study highlights associations between reproductive history and biological aging. These findings underscore the importance of considering both natural and surgical factors in menopause in evaluating aging-related health risks and suggest avenues for targeted interventions to mitigate health risks in women with these reproductive histories.
- 3 June 2025
- Published by Wolters Kluwer Health in Menopause
- Vol. 32 (8) , 692-701
Open AccessEarly menopause, hysterectomy, and biological aging: Health and Retirement Study
Objective: This study examines the association between the timing of menopause and hysterectomy and biological aging, focusing on epigenetic and physiological aging markers. Methods: Data were analyzed from women aged 56 and over in the nationally representative Health and Retirement Study (HRS). Regressions of biological aging measured by accelerated epigenetic aging and biological age based on physiological dysregulation on menopause/hysterectomy history were conducted to examine associations of normal-aged and early menopause with and without hysterectomy with biological aging. Results: Hysterectomy, whether following normal-aged or early menopause, or in younger ages, was significantly associated with markers of accelerated biological aging. Women with early menopause or hysterectomy showed accelerated epigenetic aging. Early menopause was associated with accelerated physiological dysregulation only when combined with hysterectomy, suggesting that surgical menopause may be related to accelerated systemic aging processes. Epigenetic clocks were associated with early cellular and molecular aging changes linked to natural early menopause, while physiological dysregulation was associated with the cumulative systemic impacts related to hysterectomy. Conclusions: This study highlights associations between reproductive history and biological aging. These findings underscore the importance of considering both natural and surgical factors in menopause in evaluating aging-related health risks and suggest avenues for targeted interventions to mitigate health risks in women with these reproductive histories.